Prospective and Retrospective Breast Cancer Database

August 25, 2016 updated by: Institut Claudius Regaud

Creation of a Prospective and Retrospective Breast Cancer Database

In order to accelerate border crossing between basic research and clinical research in breast cancer, it is necessary to easily use clinical and biological data. That is the reason why it is very important to create a clinical, biological and pathologic beast cancer database, mainly prospective but also retrospective. All data are from patients treated in Toulouse Centre.

The scientific community will easily have access to clinical and biological informations through a centralized, structured database , leading to optimize patients with breast cancer treatment.

Study Overview

Status

Recruiting

Conditions

Breast Cancer

Intervention / Treatment

Other: clinical biological database collection

Study Type

Observational

Enrollment (Anticipated)

10000

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Name: Florence DALENC, MD
Phone Number: 33 5 31 15 51 22
Email: dalenc.florence@iuct-oncopole.fr

Study Locations

France
- - Toulouse, France, 31059
    - Recruiting
    - Institut Claudius regaud IUCT Oncopole
    - Contact:
      
      Florence DALENC, MD
      
      Phone Number: 33 5 31 15 51 22
      
      Email: dalenc.florence@iuct-oncopole.fr

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

Genders Eligible for Study

Female

Sampling Method

Non-Probability Sample

Study Population

Female patient with breast cancer of any stage

Description

Inclusion Criteria:

Female patient
Histologically confirmed breast cancer of any stage
Affiliated to a social security system in france
Who signed the informed consent

Exclusion Criteria:

Any psychiatric or medical condition that would make the patient unable to give a signed informed consent

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Database of patients with breast cancer Time Frame: 10 years	10 years

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Institut Claudius Regaud

Investigators

Principal Investigator: Florence DALENC, MD, Institut Claudius Regaud Toulouse Oncopole

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

February 1, 2015

Primary Completion (Anticipated)

January 1, 2025

Study Completion (Anticipated)

December 1, 2025

Study Registration Dates

First Submitted

July 28, 2016

First Submitted That Met QC Criteria

August 25, 2016

First Posted (Estimate)

August 31, 2016

Study Record Updates

Last Update Posted (Estimate)